EGFR and non-small cell lung carcinoma: For head and neck squamous cell carcinoma and non-small cell lung cancer, deguelin significantly reduced the migration ability of cells by targeting epidermal growth factor receptor (EGFR) and its downstream PI3K/Akt and mitogen activated protein kinase/extracellular signal regulated kinase (MEK/ERK) signaling pathways (Baba et al., 2015; Baba et al., 2017; Gao et al., 2020; Mittal et al., 2020).